Search results for: psoriasis

Dermatology Case Answer C: May

Alisa Femia, MD and Joseph F. Merola, MD | May 14, 2013

C) Tumor necrosis factor (TNF)–α-induced palmoplantar pustular psoriasis

Dermatology Case Question: May

Alisa Femia, MD, and Joseph F. Merola, MD | May 1, 2013

Test your diagnostic knowledge with this cutaneous eruption on the palms and soles

ACR Winter Rheumatology Symposium: New Kinase Inhibitors Show Promise

Staff | May 1, 2013

Toxicity and appropriate targeting are challenges for small molecule researchers

Rheumatology Drug Updates

Michele B. Kaufman, PharmD, BCGP | May 1, 2013

Information on new approvals and medication safety that rheumatologists need to know

Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis

John Kirwan, MD | April 1, 2013

A combination therapy with glucocorticoids may be the gold standard for treating patients with rheumatoid arthritis (RA)

ACR/ARHP Annual Meeting 2012: Spondylarthritis Criteria Changing Landscape of the Disease

Thomas R. Collins | December 1, 2012

More finely tuned view of ankylosing spondylitis leads to better treatment, expert says

What Rheumatologists Should Look for in Diagnosing SAPHO Syndrome

Richard Brasington, MD | November 1, 2012

SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is an obscure condition that can vex patients and clinicians

A Few Acronyms and Indices in OMERACT

Prakash Pispati, MD | October 17, 2012

HAQ: Health Assessment Questionnaire DAS28: Disease Activity Score DAS: Psoriatic Arthritis: ACR Core Data Set and Disease Activity Score PsARC: Psoriatic Arthritis Response Criteria PSAI: Psoriasis Area and Severity Index SLEDAI: SLE Disease Activity Score BILAG: British Isles Lupus Activity Score SLAM: Systemic Lupus Activity Measure LAI: Lupus Activity Index ECLAM: European Consensus Lupus Activity…

Drug Updates: Lorcaserin, Acetaminophen, and More

Michele B. Kaufman, PharmD, BCGP | September 5, 2012

information on new approvals and medication safety

American College of Rheumatology Leads Charge to Address Excessive Patient Cost Sharing

Staff | August 8, 2012

The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.